NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024)

NovaBridge Biosciences (NBP) reported Capital Expenditures of -$38000.0 for Q4 2024, down 3700.0% quarter-over-quarter from -$1000.0 in Q3 2024.

NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024) Analysis & Trends

NovaBridge Biosciences (NBP) has 3 years of Capital Expenditures data on file, last reported at -$38000.0 in Q4 2024.

Capital Expenditures for Q4 2024 came in at -$38000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$39000.0 (down 103.2% YoY), and the FY2025 annual result was -$7000.0, up 85.42% from the prior year.
Capital Expenditures retreated to -$38000.0 in Q4 2024 per NBP's latest filing, from -$1000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $1.9 million in Q4 2020 and troughed at -$668360.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	133.40 Mn
9	Abivax	90.15 Bn	90.15 Bn	-	-63,220.27
10	NovaBridge Biosciences	328.19 Mn	117.34 Mn	-	-

Download Data